Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 2/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120610 | 0.86 | PTGS1 (0.42) | PTGS1TRPV1GPBAR1NOTUMFFAR4 | |
| SCHEMBL2118466 | 0.79 | TRPV1 (0.44) | PTGS1TRPV1GPBAR1STAT3STAT1 | |
| SCHEMBL2120590 | 0.73 | TRPV1 (0.58) | TRPV1GPBAR1STAT3STAT1MEN1 | |
| SCHEMBL13542853 | 0.69 | ALDH1A1 (0.58) | MEN1KMT2AMAPT | |
| SCHEMBL2774983 | 0.69 | GPBAR1 (0.47) | GPBAR1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL11263501 | 0.68 | MLYCD (0.51) | TRPV1GPBAR1STAT3STAT1MEN1 | |
| SCHEMBL5904590 | 0.68 | MEN1 (0.43) | TRPV1GPBAR1MEN1KMT2AMAPT | |
| SCHEMBL5904542 | 0.68 | MLYCD (0.50) | TRPV1GPBAR1MEN1KMT2AMAPT | |
| SCHEMBL2780502 | 0.68 | GPBAR1 (0.58) | GPBAR1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL2118396 | 0.67 | TRPV1 (0.57) | TRPV1GPBAR1STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095002-A1 | ISOXAZOLE-5-CARBOXAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2012-04-19 | — | — | US | disclosed |
| EP-2393788-A1 | ISOXAZOLE-5-CARBOXAMIDE DERIVATIVES | N.V. Organon (NL) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089297-A1 | ISOXAZOLE-5-CARBOXAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095002-A1 | ISOXAZOLE-5-CARBOXAMIDE DERIVATIVES | TRPV1, TRPV5, P2RX5 | PTGS1 379/4885TRPV1 1/4885GPBAR1 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.